{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:35Z","timestamp":1787800835215,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10620-026-09965-9","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:33:40Z","timestamp":1779125620000},"page":"4361-4379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Risankizumab in Crohn\u2019s Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5449-8833","authenticated-orcid":false,"given":"Alaa Abdrabou","family":"Abouelmagd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen Negmeldin","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna M.","family":"Aboelkhier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada G.","family":"Hamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman A.","family":"Elareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Saad","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen Ibrahem","family":"Gado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talaat M.","family":"elqadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elazab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser M.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Diaa","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"9965_CR1","doi-asserted-by":"publisher","first-page":"e079050","DOI":"10.1136\/bmj-2025-079050","volume":"391","author":"JG Hashash","year":"2025","unstructured":"Hashash JG, Limdi JK, Shapiro JM, Shah SA. Medical management of inflammatory bowel diseases. BMJ 2025;391:e079050. https:\/\/doi.org\/10.1136\/bmj-2025-079050.","journal-title":"BMJ"},{"key":"9965_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc 2017;92:1088\u20131103. https:\/\/doi.org\/10.1016\/j.mayocp.2017.04.010.","journal-title":"Mayo Clin Proc"},{"key":"9965_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohns Colitis 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"9965_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5009\/gnl210118","volume":"16","author":"CW Cho","year":"2022","unstructured":"Cho CW, You M-W, Oh CH et al. Long-term Disease Course of Crohn\u2019s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. Gut Liver 2022;16:157\u2013170. https:\/\/doi.org\/10.5009\/gnl210118.","journal-title":"Gut Liver"},{"key":"9965_CR5","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461\u20131463. https:\/\/doi.org\/10.1126\/science.1135245.","journal-title":"Science"},{"key":"9965_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac034","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac034.","journal-title":"J Crohns Colitis"},{"key":"9965_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut 2019;68:814\u2013828. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671.","journal-title":"Gut"},{"key":"9965_CR8","doi-asserted-by":"publisher","first-page":"622934","DOI":"10.3389\/fimmu.2021.622934","volume":"12","author":"H Schmitt","year":"2021","unstructured":"Schmitt H, Neurath MF, Atreya R. Role of the IL23\/IL17 pathway in crohn\u2019s disease. Front Immunol 2021;12:622934. https:\/\/doi.org\/10.3389\/fimmu.2021.622934.","journal-title":"Front Immunol"},{"key":"9965_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/17474124.2023.2295496","volume":"17","author":"AM Johnson","year":"2023","unstructured":"Johnson AM, Loftus EV. Risankizumab to treat moderately to severely active Crohn\u2019s disease in adults: an evaluation of trials and data. Expert Rev Gastroenterol Hepatol 2023;17:1169\u20131183. https:\/\/doi.org\/10.1080\/17474124.2023.2295496.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"9965_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"9965_CR11","unstructured":"The EndNote Team EndNote. Clarivate, Philadelphia, PA"},{"key":"9965_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"9965_CR13","unstructured":"Rohatgi A WebPlotDigitizer"},{"key":"9965_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"9965_CR15","unstructured":"Study Quality Assessment Tools | NHLBI, NIH. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 18 Jul 2025"},{"key":"9965_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"9965_CR17","unstructured":"R Foundation for Statistical Computing RCT (2024) R: A Language and Environment for Statistical Computing. Vienna, Austria"},{"key":"9965_CR18","unstructured":"Posit Software, PBC P team (2024) RStudio: Integrated Development Environment for R. Boston, MA"},{"key":"9965_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"9965_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 2022;399:2015\u20132030. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6.","journal-title":"Lancet"},{"key":"9965_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022;399:2031\u20132046. https:\/\/doi.org\/10.1016\/S0140-6736(22)00466-4.","journal-title":"Lancet"},{"key":"9965_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699\u20131709. https:\/\/doi.org\/10.1016\/S0140-6736(17)30570-6.","journal-title":"Lancet"},{"key":"9965_CR23","doi-asserted-by":"crossref","unstructured":"Fang Y, Li J, Wu J, Zhang L (2024) Study of the Effects of Risankizumab in Moderate to Severe Crohn\u2019s Disease. Indian Journal of Pharmaceutical Sciences","DOI":"10.36468\/pharmaceutical-sciences.spl.802"},{"key":"9965_CR24","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ibd\/izad315","volume":"30","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Sabino J, Franchimont D et al. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn\u2019s Disease: A Belgian Multicentric Cohort Study. Inflamm Bowel Dis 2024;30:2289\u20132296. https:\/\/doi.org\/10.1093\/ibd\/izad315.","journal-title":"Inflamm Bowel Dis"},{"key":"9965_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf070","author":"AM Johnson","year":"2025","unstructured":"Johnson AM, Askar M, Belani S et al. A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn\u2019s disease. J Crohns Coliti. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf070.","journal-title":"J Crohns Coliti"},{"key":"9965_CR26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/ibd\/izae248","volume":"31","author":"FS Macaluso","year":"2025","unstructured":"Macaluso FS, Renna S, Fries W et al. The effectiveness of risankizumab as induction therapy for crohn\u2019s disease: data from the sicilian network for inflammatory bowel diseases. Inflamm Bowel Dis 2025;31:1178\u20131181. https:\/\/doi.org\/10.1093\/ibd\/izae248.","journal-title":"Inflamm Bowel Dis"},{"key":"9965_CR27","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.cgh.2023.11.033","volume":"22","author":"A Zinger","year":"2024","unstructured":"Zinger A, Choi D, Choi N et al. Risankizumab Effectiveness and Safety in Crohn\u2019s Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol 2024;22:1336-1338.e2. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9965_CR28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","volume":"22","author":"M Fumery","year":"2024","unstructured":"Fumery M, Caron B, H\u00e9buterne X et al. Long-term Outcome of Risankizumab in Crohn\u2019s Disease: a Real-world GETAID Study. Clin Gastroenterol Hepatol 2024;22:2451-2458.e1. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9965_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/flgastro-2024-102809","volume":"15","author":"B Zare","year":"2024","unstructured":"Zare B, Gros B, Lal N et al. Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn\u2019s disease: a real-world experience from a preapproval access programme and early access to medicines scheme. Frontline Gastroenterol 2024;15:499\u2013506. https:\/\/doi.org\/10.1136\/flgastro-2024-102809.","journal-title":"Frontline Gastroenterol"},{"key":"9965_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf162","author":"G Geeganage","year":"2025","unstructured":"Geeganage G, Gade A, Saraga A et al. Long-term Outcomes of Patients with Crohn\u2019s Disease Treated with Risankizumab. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izaf162.","journal-title":"Inflamm Bowel Dis"},{"key":"9965_CR31","doi-asserted-by":"publisher","first-page":"175628482513758","DOI":"10.1177\/17562848251375844","volume":"18","author":"C-S Chung","year":"2025","unstructured":"Chung C-S, Chang C-H, Kuo C-J et al. Efficacy and safety of Risankizumab for moderate-to-severe Crohn\u2019s disease: first Asian real-world data (STAR trial). Therap Adv Gastroenterol 2025;18:17562848251375844. https:\/\/doi.org\/10.1177\/17562848251375844.","journal-title":"Therap Adv Gastroenterol"},{"key":"9965_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/apt.18049","volume":"60","author":"M Alahmad","year":"2024","unstructured":"Alahmad M, Quraishi MN, Khan SW et al. Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther 2024;60:101\u2013102. https:\/\/doi.org\/10.1111\/apt.18049.","journal-title":"Aliment Pharmacol Ther"},{"key":"9965_CR33","unstructured":"U.S. Food and Drug Administration (2022) SKYRIZI (risankizumab-rzaa) injection, for subcutaneous or intravenous use: Highlights of prescribing information. U.S. Food and Drug Administration, Silver Spring, MD"},{"key":"9965_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/cpt.2831","volume":"113","author":"AA Suleiman","year":"2023","unstructured":"Suleiman AA, Goebel A, Bhatnagar S et al. Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn\u2019s Disease. Clin Pharmacol Ther 2023;113:839\u2013850. https:\/\/doi.org\/10.1002\/cpt.2831.","journal-title":"Clin Pharmacol Ther"},{"key":"9965_CR35","doi-asserted-by":"publisher","first-page":"175628482513387","DOI":"10.1177\/17562848251338743","volume":"18","author":"P-F Huang","year":"2025","unstructured":"Huang P-F, Huang T-Y, Cheng Y-C et al. Clinical insights into IL-23 inhibition: risankizumab for Crohn\u2019s disease through a systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol 2025;18:17562848251338744. https:\/\/doi.org\/10.1177\/17562848251338743.","journal-title":"Therap Adv Gastroenterol"},{"key":"9965_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","volume":"60","author":"M Attauabi","year":"2024","unstructured":"Attauabi M, Steenholdt C, Poulsen A et al. Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease. Aliment Pharmacol Ther 2024;60:124\u2013143. https:\/\/doi.org\/10.1111\/apt.18110.","journal-title":"Aliment Pharmacol Ther"},{"key":"9965_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S379446","volume":"17","author":"S Horst","year":"2023","unstructured":"Horst S, Cross RK. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn\u2019s Disease: Patient Selection and Reported Outcomes. Drug Des Devel Ther 2023;17:273\u2013282. https:\/\/doi.org\/10.2147\/DDDT.S379446.","journal-title":"Drug Des Devel Ther"},{"key":"9965_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel J-F et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease. N Engl J Med 2024;391:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa2314585.","journal-title":"N Engl J Med"},{"key":"9965_CR39","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.cgh.2019.11.025","volume":"18","author":"C Yzet","year":"2020","unstructured":"Yzet C, Diouf M, Le Mouel J-P et al. Complete endoscopic healing associated with better outcomes than partial endoscopic healing in patients with crohn\u2019s disease. Clin Gastroenterol Hepatol 2020;18:2256\u20132261. https:\/\/doi.org\/10.1016\/j.cgh.2019.11.025.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9965_CR40","doi-asserted-by":"publisher","first-page":"100544","DOI":"10.1016\/j.gastha.2024.08.022","volume":"4","author":"BG Feagan","year":"2025","unstructured":"Feagan BG, Colombel J-F, Panaccione R et al. Early endoscopic outcomes after risankizumab are associated with fewer hospitalizations and surgeries in crohn\u2019s disease. Gastro Hep Advances 2025;4:100544. https:\/\/doi.org\/10.1016\/j.gastha.2024.08.022.","journal-title":"Gastro Hep Advances"},{"key":"9965_CR41","doi-asserted-by":"publisher","first-page":"1475222","DOI":"10.3389\/fphar.2024.1475222","volume":"15","author":"H Su","year":"2024","unstructured":"Su H, Xiao S, Liang Z et al. Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn\u2019s disease. Front Pharmacol 2024;15:1475222. https:\/\/doi.org\/10.3389\/fphar.2024.1475222.","journal-title":"Front Pharmacol"},{"key":"9965_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jgh.16358","volume":"39","author":"X Gao","year":"2024","unstructured":"Gao X, Fujii T, Ye BD et al. Efficacy and safety of risankizumab for Crohn\u2019s disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Gastroenterol Hepatol 2024;39:55\u201365. https:\/\/doi.org\/10.1111\/jgh.16358.","journal-title":"J Gastroenterol Hepatol"},{"key":"9965_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA 2024;332:881\u2013897. https:\/\/doi.org\/10.1001\/jama.2024.12414.","journal-title":"JAMA"},{"key":"9965_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/apt.17242","volume":"57","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Ghosh S, Lee SD et al. Effect of risankizumab on health-related quality of life in patients with Crohn\u2019s disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment Pharmacol Ther 2023;57:496\u2013508. https:\/\/doi.org\/10.1111\/apt.17242.","journal-title":"Aliment Pharmacol Ther"},{"key":"9965_CR45","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","volume":"145","author":"M Ferrante","year":"2013","unstructured":"Ferrante M, Colombel J-F, Sandborn WJ et al. Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145:978-986.e5. https:\/\/doi.org\/10.1053\/j.gastro.2013.08.010.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09965-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09965-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09965-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:15:38Z","timestamp":1787800538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09965-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9965"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09965-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}